![](/img/cover-not-exists.png)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
Ferrannini, E., Seman, L., Seewaldt-Becker, E., Hantel, S., Pinnetti, S., Woerle, H. J.Volume:
15
Language:
english
Journal:
Diabetes, Obesity and Metabolism
DOI:
10.1111/dom.12081
Date:
August, 2013
File:
PDF, 625 KB
english, 2013